These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 14693730

  • 21. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.
    Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK, Wahlqvist ML.
    Urology; 2004 Sep; 64(3):510-5. PubMed ID: 15351581
    [Abstract] [Full Text] [Related]

  • 22. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.
    Heikkilä R, Aho K, Heliövaara M, Hakama M, Marniemi J, Reunanen A, Knekt P.
    Cancer; 1999 Jul 15; 86(2):312-5. PubMed ID: 10421267
    [Abstract] [Full Text] [Related]

  • 23. Circulating steroid hormone levels and risk of breast cancer for postmenopausal women.
    Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2010 Feb 15; 19(2):492-502. PubMed ID: 20086116
    [Abstract] [Full Text] [Related]

  • 24. Serum androgens: associations with prostate cancer risk and hair patterning.
    Demark-Wahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Lobaugh B, Mathias BJ, Strigo TS, Paulson DF.
    J Androl; 1997 Feb 15; 18(5):495-500. PubMed ID: 9349747
    [Abstract] [Full Text] [Related]

  • 25. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
    Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J.
    Cancer Epidemiol Biomarkers Prev; 2004 May 15; 13(5):759-64. PubMed ID: 15159307
    [Abstract] [Full Text] [Related]

  • 26. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.
    Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ.
    Cancer Epidemiol Biomarkers Prev; 2005 Sep 15; 14(9):2257-60. PubMed ID: 16172240
    [Abstract] [Full Text] [Related]

  • 27. Androgens and prostate cancer risk: a prospective study.
    Wirén S, Stocks T, Rinaldi S, Hallmans G, Bergh A, Stenman UH, Kaaks R, Stattin P.
    Prostate; 2007 Aug 01; 67(11):1230-7. PubMed ID: 17562541
    [Abstract] [Full Text] [Related]

  • 28. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
    Hsing AW, Comstock GW.
    Cancer Epidemiol Biomarkers Prev; 1993 Aug 01; 2(1):27-32. PubMed ID: 8420607
    [Abstract] [Full Text] [Related]

  • 29. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer.
    Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL.
    Cancer Res; 1990 Jan 01; 50(1):169-73. PubMed ID: 2293551
    [Abstract] [Full Text] [Related]

  • 30. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS.
    Cancer; 2005 Jan 01; 103(1):76-84. PubMed ID: 15540247
    [Abstract] [Full Text] [Related]

  • 31. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ.
    J Natl Cancer Inst; 1996 Aug 21; 88(16):1118-26. PubMed ID: 8757191
    [Abstract] [Full Text] [Related]

  • 32. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk.
    Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS, Carotene and Retinol Efficacy Trial Co-Investigators.
    Cancer Epidemiol Biomarkers Prev; 2001 Oct 21; 10(10):1069-76. PubMed ID: 11588133
    [Abstract] [Full Text] [Related]

  • 33. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A, Rhoden EL.
    Urology; 2006 Dec 21; 68(6):1263-7. PubMed ID: 17169647
    [Abstract] [Full Text] [Related]

  • 34. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.
    Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiébaut A, González CA, Quirós JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E.
    Endocr Relat Cancer; 2005 Dec 21; 12(4):1071-82. PubMed ID: 16322344
    [Abstract] [Full Text] [Related]

  • 35. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.
    Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Vogelman JH, Imperato-McGinley J, Lobo RA, Orentreich N.
    Cancer Epidemiol Biomarkers Prev; 1997 Jan 21; 6(1):21-4. PubMed ID: 8993793
    [Abstract] [Full Text] [Related]

  • 36. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.
    Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D.
    J Natl Cancer Inst; 2005 Mar 02; 97(5):396-9. PubMed ID: 15741576
    [Abstract] [Full Text] [Related]

  • 37. Sex hormone ratio changes in men and postmenopausal women with coronary artery disease.
    He H, Yang F, Liu X, Zeng X, Hu Q, Zhu Q, Tu B.
    Menopause; 2007 Mar 02; 14(3 Pt 1):385-90. PubMed ID: 17108845
    [Abstract] [Full Text] [Related]

  • 38. Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial.
    King IB, Kristal AR, Schaffer S, Thornquist M, Goodman GE.
    Cancer Epidemiol Biomarkers Prev; 2005 Apr 02; 14(4):988-92. PubMed ID: 15824175
    [Abstract] [Full Text] [Related]

  • 39. Serum sex hormones and breast cancer risk factors in postmenopausal women.
    Lamar CA, Dorgan JF, Longcope C, Stanczyk FZ, Falk RT, Stephenson HE.
    Cancer Epidemiol Biomarkers Prev; 2003 Apr 02; 12(4):380-3. PubMed ID: 12692114
    [Abstract] [Full Text] [Related]

  • 40. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T, Santti H, Schatzl G, Gsur A, Haidinger G, Palvimo JJ, Jänne OA, Madersbacher S.
    Prostate; 2003 May 15; 55(3):194-8. PubMed ID: 12692785
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.